Moody Aldrich Partners LLC Has $6.17 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Moody Aldrich Partners LLC lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 96,737 shares of the biopharmaceutical company's stock after selling 10,878 shares during the period. Halozyme Therapeutics comprises approximately 1.3% of Moody Aldrich Partners LLC's holdings, making the stock its 19th biggest holding. Moody Aldrich Partners LLC owned about 0.08% of Halozyme Therapeutics worth $6,173,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $29,000. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Bessemer Group Inc. raised its holdings in shares of Halozyme Therapeutics by 62.9% in the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. Finally, Park Place Capital Corp raised its holdings in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research analyst reports. Morgan Stanley cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partnrs downgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a research report on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and an average price target of $61.90.

Halozyme Therapeutics Stock Up 0.4%

NASDAQ HALO traded up $0.22 during trading hours on Monday, reaching $54.22. 1,752,741 shares of the company's stock were exchanged, compared to its average volume of 1,756,223. The company's 50-day moving average is $55.49 and its two-hundred day moving average is $56.70. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $70.51. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. The company has a market capitalization of $6.68 billion, a price-to-earnings ratio of 14.42, a price-to-earnings-growth ratio of 0.36 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. During the same period in the prior year, the business earned $0.79 EPS. Halozyme Therapeutics's revenue for the quarter was up 35.2% compared to the same quarter last year. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 4,497 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director directly owned 28,611 shares of the company's stock, valued at $1,727,246.07. This trade represents a 13.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $39,422,721.87. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 44,497 shares of company stock valued at $2,405,284 over the last ninety days. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.